Finance

Beta
Roʻyxatlar
500124:BOM
Dr Reddy's Laboratories Ltd
1 273,80 ₹
-0,10%
(-1,25) 1K
12-iyn, 15:30:00 (GMT+5:30)  ·   INR
Barcha belgilar
BelgiNarxiOʻzgartirishlarDinamika (%)
500124 tikeri uchun statistika yaratilmoqda...
Ochish
1 288,25 ₹
Yuqori
1 288,25 ₹
Past
1 266,00 ₹
Bozor kapitali
1,06 trln
Oʻrtacha hajm
63,21 ming
Hajmi
16,56 ming
Dividend
0,63%
Choraklik dividendlar
2,00 ₹
Eks-dividend sanasi
10-iyl, 2026
P/E koeffitsiyenti
25,30
52 haftalik eng yuqori
1 377,95 ₹
52 haftalik eng past
1 149,00 ₹
Aksiya boʻyicha daromad
50,35 ₹
Muomaladagi aksiyalar
166,06 mln
Xodimlar soni
28 ming
Ochish
1 288,25 ₹
Yuqori
1 288,25 ₹
Past
1 266,00 ₹
Bozor kapitali
1,06 trln
Oʻrtacha hajm
63,21 ming
Hajmi
16,56 ming
Dividend
0,63%
Choraklik dividendlar
2,00 ₹
Eks-dividend sanasi
10-iyl, 2026
P/E koeffitsiyenti
25,30
52 haftalik eng yuqori
1 377,95 ₹
52 haftalik eng past
1 149,00 ₹
Aksiya boʻyicha daromad
50,35 ₹
Muomaladagi aksiyalar
166,06 mln
Xodimlar soni
28 ming
Yangiliklar
Internetdagi manbalardan
Profil
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr. Wikipedia
Dr Reddy's Laboratories Ltd haqida
CEOErez Israeli
Xodimlar soni27,5 ming
Asos solingan1984
Bosh ofislarHaydarobod, Andhra Pradesh, Hindiston
Sektor-
Veb-saytdrreddys.com
Avvalgi hisobotlarBarcha qiymatlar – INR
Loading Previous Earnings...
Daromad hisoboti
Daromad
Sof foyda
Barcha qiymatlar – INR
iyn, 2025
sen, 2025
dek, 2025
mar, 2026
Daromad
85,45 mlrd
88,05 mlrd
87,27 mlrd
75,16 mlrd
Sotilgan mahsulotning tannarxi
36,82 mlrd
39,91 mlrd
40,46 mlrd
41,47 mlrd
Daromad narxi
36,82 mlrd
39,91 mlrd
40,46 mlrd
41,47 mlrd
Tadqiqot va ishlanmalarga xarajatlar
6,24 mlrd
6,20 mlrd
6,15 mlrd
5,46 mlrd
Tadqiqot va ishlanmalarga xarajatlar jami xarajatlar
-
-
-
-
Tijoriy, umumiy va maʼmuriy xarajatlar
25,65 mlrd
26,44 mlrd
26,92 mlrd
27,76 mlrd
Operatsion xarajatlar
31,11 mlrd
31,90 mlrd
32,48 mlrd
32,53 mlrd
Jami operatsion xarajatlar
67,94 mlrd
71,81 mlrd
72,94 mlrd
74,00 mlrd
Operatsion daromad
17,52 mlrd
16,24 mlrd
14,33 mlrd
1,16 mlrd
Boshqa nooperatsion daromad
-
1,28 mlrd
570,00 mln
512,00 mln
Soliq toʻlangunga qadar foyda, shu jumladan gʻayrioddiy moddalar
19,05 mlrd
18,35 mlrd
15,43 mlrd
1,99 mlrd
Soliq toʻlangunga qadar foyda, gʻayrioddiy moddalar bundan mustasno
18,36 mlrd
17,81 mlrd
15,52 mlrd
1,82 mlrd
Daromad soligʻi boʻyicha xarajat
4,95 mlrd
4,08 mlrd
3,53 mlrd
-214,00 mln
Amaldagi soliq stavkasi
25,99%
22,24%
22,90%
-10,75%
Boshqa operatsion xarajatlar
-779,00 mln
-740,00 mln
-591,00 mln
-693,00 mln
Sof foyda
14,18 mlrd
14,37 mlrd
12,10 mlrd
2,20 mlrd
Sof foyda marjasi
16,59%
16,32%
13,86%
2,93%
Har bir aksiya foydasi
17,02
17,87
14,77
5,74
Foizlar va investitsiyalardan olingan daromadlar
1,13 mlrd
912,00 mln
796,00 mln
890,00 mln
Foizlarni toʻlash xarajatlari
-830,00 mln
-907,00 mln
-944,00 mln
-1,06 mlrd
Foizlarni toʻlash boʻyicha sof xarajatlar
298,00 mln
5,00 mln
-148,00 mln
-167,00 mln
Amortizatsiya ajratmalari
-
-
-
-
EBITDA
22,28 mlrd
21,29 mlrd
19,54 mlrd
5,03 mlrd
Aktivlarni sotishdan olingan foyda yoki zarar
40,00 mln
-308,00 mln
-179,00 mln
-2,10 mlrd
AI kontentda xatolar boʻlishi mumkin. Batafsil

Tahlil

AI kontentda xatolar boʻlishi mumkin. Batafsil